Research programme: matrix metalloproteinase inhibitors - Johnson & Johnson Pharmaceutical Research and Development, LLC
Latest Information Update: 04 Nov 2017
At a glance
- Originator Johnson & Johnson Pharmaceutical Research & Development
- Class
- Mechanism of Action Metalloprotease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
- 16 Apr 2003 3-Dimensional Pharmaceuticals has been acquired by Johnson & Johnson